SIRPA and neoplasm: The intricate interplay between the tumor microenvironment (TME), tumor immune evasion, cancer prognosis, and therapeutic responses has been elucidated [21, 22], highlighting the significance of targeting the CD47/SIRPα axis to impede phagocytosis and counteract innate immunity checkpoints associated with tumor immune evasion.